JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

JP Morgan analyst Joyce Zhou has initiated coverage on Hemab Therapeutics Holdings (NASDAQ: COAG) with an Overweight rating. The firm has set a price target of $70 for the stock.